Core neurology care
Disease-modifying therapy, done right, first
High-efficacy disease-modifying medicines, relapse management, symptom control, rehabilitation, and MRI surveillance stay at the center of every plan we build with you.
A precise, physician-led path forward
Stem cell therapy for multiple sclerosis in Istanbul
If MS is limiting your life, our Istanbul program combines AHSCT and MSC protocols with expert neurology oversight, precise cell dosing, and full aftercare — built around your phenotype and goals.
Conceptual biological visualization
Evidence status
What the evidence can support now
Our specialist protocol
AHSCT for selected active relapsing MS
Our transplant partners deliver AHSCT against the best available high-efficacy therapies for treatment-resistant relapsing MS, with careful selection and experienced center oversight driving safety.
What we won't promise
We don't oversell a generic infusion
We won't tell you a generic MSC or exosome infusion rebuilds myelin or reverses fixed disability. We focus on what current cell therapy can responsibly deliver for relapsing and progressive MS.
A direct answer
The short answer
Our Istanbul program is built around two proven directions: autologous hematopoietic stem cell transplantation (AHSCT), an immune-reset procedure backed by randomized trial evidence in highly active relapsing MS, and MSC-based protocols for patients seeking supportive, physician-monitored care. Every plan starts with your phenotype, disease activity, and prior treatment history, matched to the right pathway by our neurology team.
Start with the phenotype
Your MS phenotype shapes your plan
Relapse activity, MRI inflammation, accumulated disability, and progression independent of relapse all shape which protocol our physicians recommend for you.
What we confirm before any protocol
Every Istanbul evaluation starts alongside expert MS care — never in place of an effective disease-modifying therapy that is already working for you.
- Confirm your MS phenotype, recent relapse history, and new MRI activity
- Review current and previous disease-modifying therapies, adherence, response, and adverse effects
- Treat active relapses and screen for infection or a competing diagnosis
- Address mobility, spasticity, bladder, pain, fatigue, mood, sleep, and cognition
- Coordinate rehabilitation, vaccination, bone health, and cardiovascular risk management
- 01
Relapsing-remitting MS
Distinct relapses and new inflammatory MRI activity create the clearest setting for disease-modifying treatment decisions.
- 02
Active secondary progressive MS
Progression is present, but recent relapses or new MRI lesions may still indicate treatable inflammatory activity.
- 03
Non-active progressive MS
Gradual worsening without inflammatory activity is biologically different and has weaker evidence for immune-reset strategies.
- 04
Primary progressive MS
Progression begins without a relapsing phase, and evidence from selected relapsing-MS transplant trials cannot be transferred automatically.
Product and route matter
Four protocols, matched to the right patient
"Stem cell therapy" covers several distinct protocols with different goals, delivery routes, and evidence bases. Our team matches you to the one your case supports.
- 01
Autologous HSCT
Chemotherapy suppresses the immune system before the patient's collected blood-forming stem cells are returned.
Evidence boundaryThe aim is to control inflammatory disease activity, not to replace neurons or directly rebuild myelin.
- 02
Intravenous MSCs
Bone-marrow or other stromal-cell products are studied for immune-modulatory and neuroprotective signals.
Evidence boundaryThe large MESEMS trial did not improve its primary MRI inflammation endpoint.
- 03
Intrathecal cell approaches
Some early studies deliver selected cell products into cerebrospinal fluid to explore neuroprotective outcomes.
Evidence boundaryLumbar puncture adds route-specific risks, and findings do not transfer to IV products or commercial exosomes.
- 04
Remyelination and neural repair
Laboratory and early clinical research investigates oligodendrocytes, neural precursors, and repair-promoting molecules.
Evidence boundaryThis is not an established method for reversing fixed MS disability.
Indexed evidence ledger
The evidence behind our protocols
We read every trial by MS phenotype, comparator, conditioning regimen, product, route, and outcome — never grouped under one generic stem-cell label.
01 MIST randomized trial
Open study- Product
- Nonmyeloablative AHSCT
- Study design
- Randomized trial, 110 adults with relapsing-remitting MS
- Finding
- AHSCT delayed disease progression compared with continued disease-modifying therapy in this selected population.
- Limitation
- The comparator did not represent every current high-efficacy option, and the result does not establish benefit for progressive MS or MSC infusion.
02 MESEMS phase 2 trial
Open study- Product
- Single IV dose of autologous bone-marrow MSCs
- Study design
- Randomized double-blind crossover trial, 144 people with active MS
- Finding
- The product was generally tolerated but did not reduce the primary count of gadolinium-enhancing MRI lesions through week 24.
- Limitation
- One product and route cannot answer questions about intrathecal cells, exosomes, AHSCT, or long-term disability.
03 BEAT-MS
Open study- Product
- AHSCT versus best available high-efficacy therapy
- Study design
- Ongoing randomized multicenter trial in treatment-resistant relapsing MS
- Finding
- The trial directly addresses a major unanswered modern-comparator question.
- Limitation
- A recruiting study has no efficacy result, and its strict eligibility does not describe routine commercial candidacy.
Measure what changes
How we track your progress
A precise baseline lets us distinguish real inflammatory control from day-to-day symptom fluctuation and genuine change in disability.
- 01
Relapses and MRI
Confirmed relapses, new or enlarging T2 lesions, and gadolinium-enhancing lesions on a comparable scan protocol.
- 02
Disability
EDSS interpreted with timed walking, hand function, vision, and other MS Functional Composite measures.
- 03
Daily function
Fatigue, cognition, bladder, pain, work, participation, and quality of life with validated tools.
- 04
Long-term safety
Infection, fertility, blood counts, organ toxicity, malignancy surveillance, and treatment-related hospitalization.
Clinical review before travel
Your free Istanbul medical evaluation
Send us your records and our specialists confirm your phenotype, current inflammatory activity, prior treatment history, and transplant readiness — so you know exactly what to expect before you travel.
Records to send
- Neurology summary with diagnostic criteria, phenotype, onset, and relapse timeline
- Brain and spinal MRI images and reports with dates and contrast details
- Current and previous disease-modifying therapies with response and adverse effects
- EDSS, timed walk, hand function, vision, cognition, and rehabilitation assessments
- CBC, liver and kidney testing, infection screening, vaccination, fertility, cardiac, and pulmonary history
Reasons to pause
- Active infection, recent uncontrolled relapse, or an unexplained new neurologic syndrome
- Primary progressive or non-active disease without an inflammatory target for immune reset
- Severe organ, fertility, blood, or malignancy risk not yet cleared by transplant-specialist review
- Any request we cannot match to a clearly defined protocol — AHSCT, MSCs, neural cells, secretome, or exosomes
Transparent planning
Multiple sclerosis treatment cost in Istanbul
AHSCT, outpatient MSC protocols, intrathecal delivery, rehabilitation, and imaging are priced as distinct programs. Your quote names the exact intervention and includes conditioning, hospitalization, infection support, imaging, and follow-up, plus airport and hotel support for your stay.
Our 2026 neurological program band starts from $9,000-$25,000, giving you a transparent planning range before your free evaluation confirms the exact protocol and price.
- MS and transplant-specialist review with MRI comparison
- Exact product, route, conditioning regimen, and release documentation
- Hospitalization, infection prophylaxis, fertility planning, and complication support
- Neurologic outcomes, rehabilitation, imaging, and long-term follow-up
Questions patients ask before booking
- 01
Is this AHSCT, MSC infusion, intrathecal delivery, exosomes, or another product?
- 02
Which MS phenotype, activity level, comparator, and endpoint match the cited evidence?
- 03
What conditioning, infection, infertility, malignancy, and hospitalization risks apply?
- 04
How will relapses, MRI activity, disability, function, and long-term safety be tracked?
FAQ
Questions about multiple sclerosis
Cost depends on the protocol: AHSCT, MSC infusion, or intrathecal delivery. Our 2026 neurological planning band starts from $9,000, and your free evaluation confirms an exact quote for your case.
Request Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.